Table 1. Characteristics of included studies.
| First author | Year | Country | Eyes | Study design | Glaucoma | Age | Sex: female, % | Baseline | Follow-up | MINORS scores | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IOP | No. of medications | ||||||||||
| XEN (with or without phacoemulsification) vs. trabeculectomy | |||||||||||
| Marcos Parra (29) | 2019 | Spain | 121 | Retrospective | OAG | 71.0±9.15 | 51.2 | 19.84±5.38 | 2.3±0.82 | 12 m | 18 |
| Olgun (30) | 2020 | Turkey | 80 | Prospective | OAG | 61.7±13.92 | 56.5 | 25.8±7.04 | 3.56±0.50 | 3 m | 20 |
| Sacchi (31) | 2020 | Italy | 52 | Prospective | OAG | 61.1±11.98 | 60 | 25.45±2.73 | NA | 6 m | 18 |
| Schlenker (32) | 2017 | Canada | 354 | Retrospective | Different types | 66.4±61.32 | 50.3 | 24.0±8.89 | 3.0±0.74 | 12 m | 16 |
| Teus (33) | 2019 | Spain | 25 | Prospective | OAG | 71.2±10.68 | 28 | 19.3±5.65 | 0.32±0.52 | 1.5 m | 21 |
| XEN + cataract surgery vs. XEN alone | |||||||||||
| Fea (34) | 2020 | Italy | 137 | Prospective | Different types | 70.3±11.8 | 50 | 25.1±8.14 | 3.03±1 | 12 m | 19 |
| Kalina (35) | 2019 | USA | 47 | Prospective | Different types | 78.15±8.55 | 66.7 | 22.34±7.34 | 2.96±1.20 | 12 m | 19 |
| Karimi (36) | 2018 | UK | 259 | Retrospective | Different types | 74.8±11.5 | 44.4 | 19.3±6.15 | 2.6±0.82 | 18 m | 18 |
| Lenzhofer (37) | 2019 | Austria | 137 | Prospective | OAG | 70.47±11.96 | 51.1 | 22.95±6.39 | 2.95±0.95 | 24 m | 18 |
| Mansouri (38) | 2019 | Switzerland | 149 | Prospective | OAG | 74.4±9.4 | 71.7 | 20.0±7.1 | 1.9±1.3 | 24 m | 21 |
| Marcos Parra (29) | 2019 | Spain | 121 | Retrospective | OAG | 71.0±9.15 | 51.2 | 19.1±5.47 | 2.2±0.89 | 12 m | 18 |
| Reitsamer (39) | 2019 | Austria | 202 | Prospective | OAG | 71.8±10.5 | 51.4 | 21.4±3.61 | 2.6±0.91 | 24 m | 20 |
| Wałek (40) | 2020 | Poland | 39 | Prospective | OAG | 67±12.29 | 51 | 23±4.62 | 3±1.54 | 8 m | 19 |
No., number; MINORS, the methodological index for non-randomized studies (total: 24 points); OAG, open-angle glaucoma; m, months.